AptarGroup, Inc. (NYSE:ATR) Q4 2022 Earnings Conference Call February 17, 2023 9:00 AM ET
Company Participants
Mary Skafidas - SVP, IR & Communications
Stephan Tanda - President & CEO
Bob Kuhn - EVP & CFO
Conference Call Participants
Matthew Krueger - Baird
George Staphos - Bank of America
Daniel Rizzo - Jefferies
Kyle White - Deutsche Bank
Gabe Hajde - Wells Fargo Securities
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2022 Fourth Quarter Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Introducing today's conference call is Ms. Mary Skafidas, Senior Vice President of Investor Relations and Communications. Please go ahead.
Mary Skafidas
Thank you. Hello everyone and thanks for being with us today. Joining me on the call are Stephan Tanda, President and CEO; and Bob Kuhn, Executive Vice President and CFO. Our press release and accompanying slide deck have been posted to our website. If you are following along on our website, you can advance the slide by hovering over the presentation screen and clicking on the arrows on the right and left. As always we will also post a replay of this call on our website.
Today's call includes some forward-looking statements. Please refer to our SEC filings to review factors that could cause actual results to differ materially from what we are discussing today. I would now like to turn the conference call over to Stephan.
Stephan Tanda
Thank you Mary and good morning everyone. We appreciate you joining us on the call today. I'm going to begin my remarks by highlighting our results for the fourth quarter and the full year. Later on in the call Bob Kuhn, our CFO will provide additional details on the quarter and year-end results. I will also spend some time talking about the strategic realignment that we announced in early December and the benefits we expect to achieve.
Starting on Slide 3 for the fourth quarter, I’m pleased to report that Aptar achieved core sales growth of 4% and delivered adjusted EPS of $0.92 per share. We guided our adjusted earnings per share for the fourth quarter to be in the range of $0.73 to $0.83. The results are driven by strong volume growth in our pharma segment, which continue to benefit from demand for nasal decongestants and saline rinses, as well as allergic rhinitis and emergency medications.